Peptide · Research Monograph · Synthetic pentadecapeptide (15 amino acids)

BPC-157

Pentadecapeptide · Preclinical Models

BPC-157 is a synthetic peptide, 15 amino acids long. It copies part of a larger protein found in human stomach fluid. Research in animal models has measured new blood vessel growth, how tendon cells move and spread, and how tissue remodels after injury. It holds up in stomach acid better than most peptides, which is unusual and has been studied on its own.

For laboratory research use only - not for human or animal use

Available in the Eon catalog - BPC-157 from $60.00 Certificate of analysis (PDF)

Molecular data

Molecular formulaC62H98N16O22
Molecular weight1419.53 Da
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Sequence length15 residues
CAS / identifier137525-51-0
Physical formLyophilized powder
Available sizes10mg, 20mg

How it works

VEGF Pathway

VEGF & Angiogenic Signalling

In preclinical models, raised vascular endothelial growth factor (VEGF) expression has been measured following BPC-157 exposure, with vessel formation and perfusion recorded in the same models.

  • Vessel formation measured in animal models (angiogenesis)
  • Raised VEGF receptor expression reported
  • Modulates nitric oxide signaling (NO system)
Growth Hormone

GHR Upregulation

Growth hormone receptor expression in cultured tendon fibroblasts has been measured at approximately 7× baseline within 3 days of exposure.

  • 7× growth hormone receptor upregulation
  • Tendon fibroblast viability measured in culture
  • Collagen synthesis signalling examined
Cytoprotective

Cytoprotective Signalling

Cytoprotective endpoints have been examined across several organ systems in animal studies, most often in gastrointestinal and musculoskeletal tissue.

  • Gastric mucosal integrity endpoints
  • Faster wound closure recorded in animal models
  • Neuroprotective endpoints observed in rodent models

What the research shows

Musculoskeletal

Tendon & Ligament

Achilles tendon, MCL and rotator cuff models in rats, with collagen fibre organisation among the measured endpoints.

Gastrointestinal

Gastrointestinal Models

Cytoprotective endpoints examined in NSAID-induced injury, alcohol lesion and colitis models.

Neuroprotective

Brain & Nervous System

Neuroprotective endpoints examined in traumatic brain injury and peripheral nerve models, including functional markers.

Vascular

Vascular Models

Studied for angiogenesis after surgical transection in animal models, via NO system modulation.

Specification

SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Weight1419.53 Da
Molecular FormulaC₆₂H₉₈N₁₆O₂₂
FormLyophilized powder (5mg)
Purity≥99% (HPLC verified)
TestingThird-party HPLC, Mass Spec, Endotoxin
Storage-20°C for long-term stability
SolubilityWater-soluble
COAIncluded with every order

Frequently asked questions

What is BPC-157 and where does it come from?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a larger protein found in human gastric juice. It was first characterised at the University of Zagreb, Croatia, and has been studied extensively in animal models across cytoprotective and tissue-remodelling endpoints.

Is BPC-157 FDA approved?

No. BPC-157 is not approved by the FDA or any regulatory agency for human use. It is classified as an unapproved drug. The FDA has issued warnings about BPC-157 being found in compounded products and dietary supplements. Only one Phase I clinical trial has been registered, and no Phase 2 or 3 trials have been completed.

What does the research show about BPC-157?

Preclinical research (animal studies) has reported BPC-157 in tendon, ligament, muscle and bone models; in gastrointestinal lesion and inflammation models; in neuroprotection models of brain injury; and in blood-vessel formation. All findings are from animal studies - no human clinical data exists.

How is BPC-157 used in research settings?

BPC-157 has been studied in rodent models and in cultured cell systems, with tissue-remodelling and gastrointestinal endpoints. Study design, concentrations and endpoints differ between experiments.

What are the safety concerns with BPC-157?

No lethal dose was reached in preclinical toxicology studies, and no significant adverse effects have been reported in published research. However, BPC-157 has never completed human clinical trials, so its safety profile in humans is unknown. It should only be used for in vitro laboratory research.

How should BPC-157 be stored?

Lyophilized (powder) form should be stored at -20°C for long-term stability, protected from light and moisture. BPC-157 is a stable peptide — published work reports resistance to hydrolysis, enzymatic degradation, and gastric acid.

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.